報價延遲最少15分鐘:2026/03/26 05:13 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.15
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.39/-1.19
|
|
企業價值
2.21B
|
| 資產負債 |
|
每股賬面淨值
1.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
276.98M
|
|
每股收益
1.23
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product,clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment. |
